Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Sarcoma × Lapatinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 23 Neoplasms 3 Neoplasm Metastasis 3 Stomach Neoplasms 1 Sarcoma 1 Osteitis Deformans 1 Neoplastic Cells, Circulating 1 Invasive Breast Cancer 1 Head and Neck Neoplasms 1 HER2-positive Advanced Breast Cancer 1 HER2+ Metastatic Breast Cancer (MBC) 1 HER2 Positive Metastatic Breast Cancer 1 Esophageal Neoplasms 1 Carcinoma 1 Breast Neoplasms, Male 1 Brain Neoplasms 1

Interventions

Doxorubicin 22 Ifosfamide 19 Radiotherapy 14 Vincristine 9 Etoposide 9 Filgrastim 8 Cyclophosphamide 8 Trabectedin 7 Dactinomycin 7 pazopanib 4 Cisplatin 4 Topotecan 3 Radiation 3 Irinotecan 3 Granulocyte Colony-Stimulating Factor 3 Chemotherapy, Adjuvant 3 sargramostim 2 etoposide phosphate 2 eribulin 2 Observation 2 Methotrexate 2 Mesna 2 Imatinib Mesylate 2 Gemcitabine 2 Docetaxel 2 Dexrazoxane 2 Dacarbazine 2 trofosfamide 1 trioctyl phosphine oxide 1 trametinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡